Ivabradine Mercury Pharmaceuticals

Active Ingredient:: Ivabradine Hydrochloride
Origin:: EU

Ivabradine Mercury Pharmaceuticals (Ivabradine Hydrochloride)

Q: What conditions is Ivabradine Mercury Pharmaceuticals used for?

Ivabradine Mercury Pharmaceuticals is prescribed to manage chronic stable angina and to alleviate symptoms in patients with heart failure by lowering the heart rate without affecting contractility.

Q: How does ivabradine work to treat these conditions?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which slows the pacemaker activity of the heart, resulting in a reduced heart rate and lower myocardial oxygen demand.

Q: What is the usual dose of ivabradine?

The dosage of ivabradine is individualized by the prescribing clinician based on the patient’s heart rate, clinical condition, and response to therapy. Patients should follow the prescriber’s instructions precisely.

Q: Is ivabradine safe during pregnancy or breastfeeding?

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Q: How do I order Ivabradine Mercury Pharmaceuticals from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does ivabradine compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or insufficient.

Q: What are the recommended storage conditions for this product?

Store at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed.

Q: How is ivabradine administered?

Ivabradine is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed.

Q: What are the most serious risks associated with ivabradine?

Serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, high‑grade atrioventricular block, and rare visual disturbances that may progress to persistent vision loss.

Q: Who should not use ivabradine?

Ivabradine is contraindicated in patients with severe hypotension, sick sinus syndrome, acute decompensated heart failure, or those taking strong CYP3A4 inhibitors without dose adjustment. It should also be avoided in individuals with known hypersensitivity to the drug.

Ivabradine, the active ingredient in Ivabradine Mercury Pharmaceuticals, is an If channel inhibitor presented as an oral tablet for systemic use. It is indicated for the management of chronic stable angina and for symptomatic relief in patients with heart failure, primarily in adult populations.

GNH India supplies Ivabradine Mercury Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product integrity throughout the supply chain.

Manufacturer / TM Owner

Mercury Pharmaceuticals Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac If channel to control heart rate in ischemic and heart‑failure conditions.

Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate.
Heart failure: improves symptoms and may lower hospitalization risk by decreasing myocardial oxygen demand.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows spontaneous depolarization. This reduction in pacemaker activity lowers heart rate without affecting myocardial contractility, thereby decreasing cardiac oxygen consumption and improving coronary perfusion in patients with angina or heart failure.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

Bradycardia: resting heart rate below 50 bpm.
Visual disturbances (phosphenes): transient luminous phenomena.
Headache: mild to moderate intensity.
Dizziness or vertigo.
Fatigue or general weakness.
Blurred vision.

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical intervention.
Atrial fibrillation or other arrhythmias.
Severe hypotension.
High‑grade atrioventricular block.
Persistent visual loss.
Allergic reactions such as rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate cardiac status and concomitant medications.

Cardiac monitoring: assess baseline heart rate and rhythm.
Avoid in severe hypotension: do not start if systolic BP <90 mmHg.
Caution with sick sinus syndrome: may exacerbate bradyarrhythmias.
Do not combine with strong CYP3A4 inhibitors without dose adjustment.
Pregnancy and lactation: use only if potential benefit justifies risk.
Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Ivabradine may interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels.
Co‑administration with other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia.
QT‑prolonging drugs (e.g., amiodarone): heightened risk of arrhythmias.

Moderate Interactions (Monitor Closely)

Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise ivabradine concentrations.
Other antiarrhythmics (e.g., flecainide): monitor heart rhythm.
CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

Frequently Asked Questions

Ivabradine Mercury Pharmaceuticals is prescribed to manage chronic stable angina and to alleviate symptoms in patients with heart failure by lowering the heart rate without affecting contractility.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which slows the pacemaker activity of the heart, resulting in a reduced heart rate and lower myocardial oxygen demand.

The dosage of ivabradine is individualized by the prescribing clinician based on the patient’s heart rate, clinical condition, and response to therapy. Patients should follow the prescriber’s instructions precisely.

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or insufficient.

Store at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed.

Ivabradine is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed.

Serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, high‑grade atrioventricular block, and rare visual disturbances that may progress to persistent vision loss.

Ivabradine is contraindicated in patients with severe hypotension, sick sinus syndrome, acute decompensated heart failure, or those taking strong CYP3A4 inhibitors without dose adjustment. It should also be avoided in individuals with known hypersensitivity to the drug.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.